COYA

Coya TherapeuticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

Curated Events

Active

Recent Headlines

New

Curated events

Materiality

earnings

Source

External coverage

Decided

2026-08-18

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

View event details3 more curated

Sentiment decomposition

30-day score

Company-55%

Macro-30%

Pulse-15%

Weekly research-10-day

Company, Macro, and Pulse form the existing 30-day artifact blend. Weekly research is tracked separately for 10 days and can contribute at most 10% of the sentiment pillar when live mode is enabled.

Recent headlines

Headline

Time

Relevance

Coya Therapeutics secures FDA fast track status for COYA 302

2026-05-14

13%

External coverage

Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

2026-05-12

28%

External coverage

NanoViricides Measles Treatment Granted Orphan Drug Designation by FDA

2026-05-06

13%

External coverage

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

2026-03-16

90%

External coverage

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

2026-01-20

28%

External coverage

Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

2026-01-08

28%

External coverage

As of 2026-08-18 • Updated scheduledSource: News desk